TENX vs. BLUE, IPSC, EPRX, VTGN, APLT, ALTS, TLSA, DERM, ADAG, and CTOR
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include bluebird bio (BLUE), Century Therapeutics (IPSC), Eupraxia Pharmaceuticals (EPRX), Vistagen Therapeutics (VTGN), Applied Therapeutics (APLT), Janone (ALTS), Tiziana Life Sciences (TLSA), Journey Medical (DERM), Adagene (ADAG), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.
Tenax Therapeutics vs.
Tenax Therapeutics (NASDAQ:TENX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.
Tenax Therapeutics has higher earnings, but lower revenue than bluebird bio.
Tenax Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 150.39%. bluebird bio has a consensus target price of $49.14, suggesting a potential upside of 489.24%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than Tenax Therapeutics.
In the previous week, bluebird bio had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for bluebird bio and 1 mentions for Tenax Therapeutics. bluebird bio's average media sentiment score of 0.97 beat Tenax Therapeutics' score of 0.75 indicating that bluebird bio is being referred to more favorably in the news media.
Tenax Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
bluebird bio received 896 more outperform votes than Tenax Therapeutics when rated by MarketBeat users. Likewise, 70.99% of users gave bluebird bio an outperform vote while only 56.03% of users gave Tenax Therapeutics an outperform vote.
1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 1.4% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Tenax Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Tenax Therapeutics' return on equity of -46.00% beat bluebird bio's return on equity.
Summary
Tenax Therapeutics beats bluebird bio on 9 of the 16 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TENX) was last updated on 1/21/2025 by MarketBeat.com Staff
